Pyridine derivative, process for its preparation and use as well as pharmaceutical composition in which the derivative is comprised

• Main Authors: FREYNE EDDY JEAN EDGARD, DIELS GASTON STANISLAS MARCELLA, DIAZ-MARTINEZ ADOLFO, MATESANZ-BALLESTEROS MARIA ENCARNACION
• Format: Patent
• Language: Czech; English
• Published: 16.01.2008
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Derivát pyridinu vzorce (I), kde -A-B- znamená dvojmocný zbytek vzorce -CR.sup.4.n.=CR.sup.5.n.-nebo -CHR.sup.4.n.=CHR.sup.5.n.-; D je O nebo NR.sup.6.n.; Q je substituovaný 2- nebo 3- pyridyl; R.sup.1.n. je H nebo C.sub.1-4.n.alkyl; R.sup.2.n.je H; halogen; C.sub.1-6.n.alkyl; trifluormethyl;C.sub.3-6.n.cykloalkyl; karboxyl; C.sub.1-4.n.alkyloxykarbonyl; C.sub.3-6.n.cykloalkylaminokarbonyl; aryl, Het.sup.1.n.; nebo C.sub.1-6.n.alkyl substituovaný kyanoskupinou, aminoskupinou, hydroxyskupinou, C.sub.1-4.n.alkylkarbonylaminoskupinou, arylskupinou nebo skupinou Het.sup.1.n.; nebo R.sup.2.n. je -O- R.sup.9.n. nebo -NH-R.sup.10.n.; R.sup.3.n. je H, halogen, hydroxy, C.sub.1-6.n.alkyl nebo C.sub.1-6.n.alkoxy; R.sup.4.n. a R.sup.5.n. je každý nezávisle H nebo C.sub.1-4.n.alkyl; R.sup.6.n. je H, C.sub.1-4.n.alkyl nebo kyano; R.sup.9.n. je H; C.sub.1-6.n.alkyl; C.sub.1-6.n.alkyl substituovaný hydroxyskupinou, karboxyskupinou, C.sub.1-4.n.alkyloxykarbonylskupinou, aminoskupinou, mono- nebo di(C.sub.1-4.n.alkyl)aminoskupinou, skupinou Het.sup.1.n. nebo arylskupinou; aryl znamená popřípadě substituovanou fenylovou skupinu; Het.sup.1.n. znamená popřípadě substituovanou heterocyklylskupinu; a jeho N-oxidová forma, farmaceuticky přijatelná adiční sůl s kyselinou nebo bází a stereochemicky izomerní forma. Tento derivát inhibuje PDE IV. Způsob jeho výroby a použití a farmaceutická kompozice s jeho obsahem. In the present invention, there is disclosed a pyridine derivative of the general formula (I), in which -A-B- represents a bivalent radical of the general formula -CRe4=CRe5- or -CHRe4=CHRe5-; D denotes an oxygen atom or NRe6; Q represents a substituted 2-alkyl or alkyl containing 1 to 4 carbon atoms; Re2 represents a hydrogen atom; a halogen atom; alkyl containing 1 to 6 carbon atoms; trifluoromethyl; cycloalkyl having 3 to 6 carbon atoms; carboxyl; alkyloxycarbonyl containing 1 to 4 carbon atoms in the alkyl moiety; cycloalkylaminocarbonyl having 3 to 6 carbon atoms in the cycloalkyl moiety; aryl, Hete1; or alkyl containing 1 to 6 carbon atoms and substituted with a cyano group, an amino group, a hydroxy group, an alkylcarbonylamino group containing 1 to 4 carbon atoms in the alkyl moiety, an aryl group or a Hete1 group; or Re2 denotes -O- Re9 or -NH-Re10; Re3 represents H, halo, hydroxy, alkyl or alkoxy containing each 1 to 6 carbon atoms; Re4 and Re5 represent independently on each other H or alkyl containing 1 to 4 carbon atoms; Re6 is H, alkyl containing 1 to 4 carbon atoms or a cyano group; Re9 represents H; alkyl containing 1 to 4 carbon atoms being substituted with a hydroxy group, a carboxy group, an alkyloxycarbonyl group having 1 to 4 carbon atoms in the alkyl moiety, an amino group, a mono- or dialkylamino group containing 1 to 4 carbon atoms in the alkyl moiety, a Hete1 or an aryl group; aryl denotes an optionally substituted phenyl group; Hete1 represents an optionally substituted heterocyclyl group; and N-oxide form, a pharmaceutically acceptable acid or base addition salt as well as stereochemically isomeric form thereof. The above-described derivative inhibits PDE IV. Disclosed is also a process for its preparation and pharmaceutical composition in which the derivative is comprised.